Alphamab Oncology has retracted its previous announcement concerning the inclusion of its anti-HER2 bispecific antibody-drug conjugate (ADC), JSKN033, in a pilot program designed to optimize the review and approval process for innovative drug clinical trials. The retraction was issued through Cision, advising journalists and readers to disregard the original news release dated November 13, 2024.
The initial announcement highlighted a Phase I/II clinical study evaluating a subcutaneous co-formulation of JSKN033. This study aimed to assess the safety and efficacy of the drug in patients with HER2-positive cancers. However, Alphamab Oncology has not provided specific reasons for the retraction.
JSKN033 is designed to target the HER2 receptor, which is overexpressed in several types of cancers, including breast and gastric cancers. ADCs like JSKN033 combine the specificity of monoclonal antibodies with the cytotoxic activity of chemotherapy drugs, aiming to selectively target and destroy cancer cells while minimizing damage to healthy tissues. The subcutaneous formulation aimed to offer a more convenient administration route compared to intravenous infusions.
The retraction leaves the status of the clinical trial and its potential inclusion in the pilot program uncertain. Further details from Alphamab Oncology are awaited to clarify the future direction of JSKN033's clinical development.
